Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Case Comprehensive Cancer Center
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01095094CT.gov Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Anaplastic Ependymoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| NORVIR (this asset) | Case Comprehensive Cancer Center | P2 | CCC · 53 |
| Dna, D(3'-Amino-3'-Deoxy-P-Thio)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-(O-(2-Hydroxy-3-((1-Oxohexadecyl)Amino)Propyl) Hydrogen Phosphorothioate) | Pediatric Brain Tumor Consortium | P2 | CCC |
| Lopinavir | Case Comprehensive Cancer Center | P2 | CCC |
| axl1717 | Rush University Medical Center | P1/2 | CCC |
| Lapatinib | National Cancer Institute (NCI) | P1 | CC |
| Trametinib | St. Jude Children's Research Hospital | P1 | CC |
| Therapeutic Allogeneic Lymphocytes | City of Hope Medical Center | P1 | CC |
| Sonidegib | St. Jude Children's Research Hospital | P1 | CC |
| Ribociclib | St. Jude Children's Research Hospital | P1 | CC |
+4 more in the Anaplastic Ependymoma cohort
Other indications for NORVIR
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Hepatitis C Virus Infection | — | P3 | BBB · 76 |
| Hepatitis C Virus Infection | — | P3 | BBB · 76 |
| HIV Infectious Disease | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Dna, D(3'-Amino-3'-Deoxy-P-Thio)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-(O-(2-Hydroxy-3-((1-Oxohexadecyl)Amino)Propyl) Hydrogen Phosphorothioate)Pediatric Brain Tumor ConsortiumCCC
- LopinavirCase Comprehensive Cancer CenterCCC
- axl1717Rush University Medical CenterCCC
- LapatinibNational Cancer Institute (NCI)CC
- TrametinibSt. Jude Children's Research HospitalCC
Citation
Floatz Terminal. NORVIR in Anaplastic Ependymoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/norvir-anaplastic-ependymoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →